Presentations

Below is a list of oral presentations given by our team, nationally and internationally.

2019

N. Willis. Small molecule inhibitors of Notum to potentiate Wnt signaling in the mammalian central nervous system. Alzheimer’s Research UK Conference 2019; March 2019; Harrogate, UK.

L.  Magno. A platform to assess primary microglia function across different states in vitro: potential for drug-screening and target validation. Alzheimer’s Research UK Conference 2019; March 2019; Harrogate, UK.

F. Svensson. Analysis of Fragment Binding Modes in Notum Crystal Structures. 7th RSC-BMCS Fragment-based drug discovery; March 2019; Cambridge, UK.

B. N. Atkinson. Discovery of 2-phenoxyacetamides as Inhibitors of the Wnt-depalmitoleating enzyme NOTUM from an X-ray Fragment Screen. 7th RSC-BMCS Fragment-based drug discovery; March 2019; Cambridge, UK.

S. Jolly. Characterisation of the CNS expression and function of Notum, a negative regulator of Wnt signalling pathway. ADPD 2019; March 2019; Lisbon, Portugal.

P. V. Fish. Development of potent, selective, CNS penetrant small molecule inhibitors of Notum to potentiate Wnt signalling. Charnwood Molecular, BioCity, Nottingham, UK; March 2019. Oral.

L. Magno. Expression and function of genetic variants of Phospholipase C-gamma2, a possible target for modulating microglial function in Alzheimer’s disease. DRI ECR Neuroinflammation Workshop, Chipping Norton, UK; April 2019. Oral.

D. Lau. A platform to assess primary microglia function across different states in vitro: potential for drug-screening and target validation. DRI ECR Neuroinflammation Workshop, Chipping Norton, UK; April 2019. Oral.

P.V. Fish. Chemical biology enabling drug discovery. Development of CNS penetrant small molecule inhibitors of Wnt-depalmitoleating enzyme NOTUM. EFMC-ACSMEDI MedChem Frontiers 2019; June 2019; Krakow, Poland.

L. Magno. A platform to assess primary microglia function across different states in vitro: potential for drug-screening and target validation. Euroglia 2019; July 2019; Porto, Portugal.

P.V. Fish. Chemical biology enabling drug discovery. Small molecule chemical tools of the Wnt-depalmitoleating enzyme NOTUM. ChemBiOx 2019; July 2019; Oxford, UK. Oral.

2018

A. Monaghan. High throughput screening in the search for new therapies for dementia: One year and one million datapoints. Alzheimer’s Research UK Conference 2018; March 2018; London, UK.

S. Jolly. Characterisation of the CNS expression and function of Notum, a negative regulator of Wnt signalling pathway. Alzheimer’s Research UK Conference 2018; March 2018; London, UK.

W. Mahy. The development of CNS penetrant small molecule inhibitors of Notum to potentiate Wnt signalling for the maintenance of synaptic function in Alzheimer’s disease. Alzheimer’s Research UK Conference 2018; March 2018; London, UK.

L. Magno. Expression and function of genetic variants of Phospholipase C-gamma2, a possible target for modulating microglial function in Alzheimer’s disease. EMBO Workshop Microglia 2018; March 2018; Heidelberg, Germany.

H. Woodward. Development of an Enantiospecific Synthetic Route to HSP co-inducer Arimoclomol and its Analogues. RSC 29th Symposium on Medicinal Chemistry in Eastern England; April 2018; Hatfield, UK.

S. Jolly. Development of a phenotypic screen in primary hippocampal neurons to investigate synaptic maintenance MRC Stem Cell Partnership Workshop. April 2018 Cardiff, Wales. Oral.

P. Whiting. Identifying Small Molecule Modulators of Huntingtin (HTT) incomplete splicing for Huntington’s disease. SLMS Grand Rounds: Huntington’s disease. May 2018; London, UK. Oral.

N. Willis. The development of CNS penetrant small molecule inhibitors of Notum to potentiate Wnt signalling for the maintenance of synaptic function in Alzheimer’s disease. RICT, Interfacing chemical biology and drug discovery; July 2018; Strasburg, France.

M. Bictash. Neu Implementation of a patient derived disease model using human iPSC for drug screening. ERIG 2018; September 2018, London, UK. Oral.

B. N. Atkinson. Development of an enantiospecific synthetic route to HSP co-inducer arimoclomol and its analogues. XXVC EFMC: International Symposium on Medicinal Chemistry 2018; September 2018; Ljubljana, Slovenia.

P. V. Fish. Development of potent, selective, CNS penetrant small molecule inhibitors of Notum to potentiate Wnt signalling. EFMC: International Symposium on Medicinal Chemistry 2018; September 2018; Ljubljana, Slovenia. Oral.

J. Sipthorp. Chemical biology approaches to assist drug development of NOTUM inhibitors. EMBO Chemical Biology 2018; September 2018; Heidelberg, Germany.

W. Mahy. Development of Potent, Selective, CNS Penetrant Small Molecule Inhibitors of Notum to Potentiate Wnt Signalling. Biochemical Society Meeting: Acylation of intracellular and secreted proteins: mechanisms and functional outcomes; September 2018; Brighton, UK. Oral.

W. Mahy. Development of Potent, Selective, CNS Penetrant Small Molecule Inhibitors of Notum to Potentiate Wnt Signalling. Small Molecule TIN Symposium: A celebration of small molecule drug discovery at UCL; September 2018; London, UK. Oral.

P. V. Fish. Development of potent, selective, CNS penetrant small molecule inhibitors of Notum to potentiate Wnt signalling. Charles River Laboratories, Harlow, UK; October 2018. Oral.

2017

P. V. Fish. New chemical probes to explore novel approaches to treat Alzheimer’s disease and cancer. Advances in Drug Discovery 2017: Academic drug Discovery; March 2017; Cambridge UK. Oral

L. Magno. RNAScope to investigate expression of markers in the brain and identify new drug targets. RNAScope Neuroscience Symposium; November 2017; London, UK. Oral.

P. V. Fish. New chemical probes to explore novel approaches to treat Alzheimer’s disease and cancer. Oxford University; November 2017. Oral.